Lenvatinib Submitted to FDA for Thyroid Cancer Approval

Share this content:

the Cancer Therapy Advisor take:

Eisai has filed a new drug application with the U.S. Food and Drug Administration (FDA) for lenvatinib for the treatment of patients with progressive radioiodine-refractory, differentiated thyroid cancer. Lenvatinib was granted orphan drug status by the FDA in February 2013.

 

The new drug application filing is based on the phase 3 double-blind, randomized, placebo-controlled SELECT study, which showed that lenvatinib delayed disease progression by 18.3 months compared with 3.6 months in the placebo group. In addition, 65% of patients taking lenvatinib experienced partial responses and 2% attained a complete response.

 

The study also found that lenvatinib caused several adverse effects, including hypertension, diarrhea, fatigue, decreased appetite, nausea, and vomiting.

 

Lenvatinib is a tyrosine kinase inhibitor that targets VEGFR1-3, FGFR1-4, PDGFR-β, KIT, and RET. If approved, lenvatinib would most likely be administered orally once daily as a 24 mg dose to patients whose differentiated thyroid cancer is 131I-refractory or -resistant following external beam radiotherapy or radiofrequency ablation.

 

Another targeted tyrosine kinase inhibitor, sorafenib, was approved by the FDA in November 2013 for radioiodine-resistant differentiated thyroid cancer.

Thyroid cancer metastases / Science Source
Lenvatinib has been submitted as a treatment for progressive thyroid cancer.

Eisai has filed its anticancer agent lenvatinib with regulators on both sides of the Atlantic. Specifically the drug has been submitted as a treatment for progressive radioiodine-refractory, differentiated thyroid cancer.

The filings, which come after a Japanese submission in June, is based on a 392-patient Phase III study which showed that lenvatinib achieved a statistically significant improvement in progression-free survival.

Related Links Eisai's lenvatinib to get speedy review in Europe Lenvatinib has orphan drug designation for thyroid cancer in the USA, Japan and in Europe, where it has granted an accelerated assessment by the European Medicines Agency, as a new medicine expected to be of major public health interest.

READ FULL ARTICLE From Pharma Times

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs